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Background: To assess the feasibility and benefit of integrating four-dimensional (4D) Positron Emission Tomography
(PET) – computed tomography (CT) for liver stereotactic body radiation therapy (SBRT) planning.
Methods: 8 patients with 14 metastases were accrued in the study. They all underwent a non-gated PET and a 4D PET
centered on the liver. The same CT scan was used for attenuation correction, registration, and considered the planning
CT for SBRT planning. Six PET phases were reconstructed for each 4D PET. By applying an individualized threshold to
the 4D PET, a Biological Internal Target Volume (BITV) was generated for each lesion. A gated Planning Target Volume
(PTVg) was created by adding 3 mm to account for set-up margins. This volume was compared to a manual Planning
Target Volume (PTV) delineated with the help of a semi-automatic Biological Target Volume (BTV) obtained from the
non-gated exam. A 5 mm radial and a 10 mm craniocaudal margins were applied to account for tumor motion and
set-up margins to create the PTV.
Results: One undiagnosed liver metastasis was discovered thanks to the 4D PET. The semi-automatic BTV were
significantly smaller than the BITV (p = 0.0031). However, after applying adapted margins, 4D PET allowed a statistically
significant decrease in the PTVg as compared to the PTV (p = 0.0052).
Conclusions: In comparison to non-gated PET, 4D PET may better define the respiratory movements of liver targets
and improve SBRT planning for liver metastases. Furthermore, non respiratory-gated PET exams can both misdiagnose
liver metastases and underestimate the real internal target volumes.
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Although surgery is the standard of care for resectable
liver metastases, less invasive local options like radiofre-
quency ablation and stereotactic body radiation therapy
(SBRT) are available with promising results [1-4]. Limi-
tations for radiation use in liver tumors (primaries or
metastases) have been two-fold historically, namely lim-
ited tumor dose shaping possibilities using tridimen-
sional irradiation due to respiratory motion and liver
radiosensitivity leading in rare occasions to lethal radiation-
induced liver disease (RILD) [1,5]. Technological advances* Correspondence: riouo@hotmail.com
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unless otherwise stated.in Radiation Oncology have dramatically changed the
management of liver tumors, with gating and tracking on
one hand and SBRT and intensity modulated radiotherapy
(IMRT) techniques on the other, both allowing more con-
formal irradiation, and reducing RILD to less than 5%
[6-8]. Treatment planning for liver radiotherapy is chal-
lenging when using computed tomography (CT) scan
alone. Contrast medium injection helps to define target
volumes but is insufficiently standardized and efficient to
reduce inter-individual variability in delineation [9]. Mag-
netic Resonance Imaging (MRI) and Positron Emission
Tomography (PET) are helpful to counteract this vari-
ability, but fusion uncertainty, mostly due to different
respiratory cycle phases, results in unreliable volume
definition when planning high precision treatment suchd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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be proposed to unresectable metastases and hepatocarci-
nomas, or patients awaiting liver grafts. Unlike for hepa-
tocarcinoma [11], [18 F]FluoroDeoxyGlucose ([18 F]FDG)
PET-CT imaging sensitivity to diagnose liver metastases
is rather high [12].
The use of PET-CT for radiotherapy planning results
in a change in target volume definition for most of the
cases (84%), with an overall CTV increase of about 25%
[13]. By contrast, four-dimensional (4D) PET-CT has
been shown to decrease target volumes in lung cancer
by as much as 34%, along with a rise in uptake values,
which theoretically leads to a better tumor definition
[14]. The usefulness of 4D PET-CT for radiotherapy
planning has been recently evaluated in lung tumors
[15,16] and for liver radiotherapy planning [10], but this
study represents the first intent to compare a planning
method with PET-CT to another incorporating 4D PET.
Methods
Liver metastases segmentation description
We investigated the reliability of establishing a personal-
ized threshold segmentation method based on normal
liver SUVmax for tumor measurements. We first evalu-
ated this method on phantom studies and then applied
the same methodology to patient cases.
This methodology is described below.
Imaging information
The PET reconstruction parameters were as following: 2
iterations, 21 subsets, Gaussian filter (FWHM= 2 mm),
2 mm slice thickness, matrix 512×512, True X (Ordered-
Subsets Expectation Maximization algorithm, Point-
Spread Function with Time-Of-Flight) (Ultra HD-PET).
Liver metastases segmentation evaluation on phantom
Phantom studies were performed with 150 seconds PET
acquisition. The CT scan was used for attenuation cor-
rection and registration for PET acquisitions. We used
the list mode of a Siemens Biograph mCT to get the six
phase of the gated PET. The Siemens Biograph mCT
was fitted with four rings and time of flight, correspond-
ing to 32 448 LSO detectors, with each detector dimen-
sion being 4 mm × 4 mm × 20 mm. The transaxial field
of view (FOV) was 50 cm and the length of the axial
direction was 21.6 cm, allowing covering the whole
phantom in one step.
First, hot spheres were imaged in a Jaszczak phantom.
The following sphere volumes (inner volume) were used:
16, 8 and 4 cc. Each sphere was successively filled to
obtain the following SUV: 2, 4 and 8, in corresponding
SUV backgrounds of 1.17, 1.19, and 1.23.
Then phantom measurements were performed on a
torso-shaped phantom, which is a semi anthropomorphicphantom more similar in shape to the patient anatomical
condition: several compartments representing the liver,
lungs, mediastinum, vertebras and spheres inside the liver
representing the liver metastases (Figure 1). Measure-
ments were made on a 16 cc sphere with a SUV of 7.9
and a background SUV of 2.97 and then on an 8 cc sphere
with a SUV of 5.6 and a background SUV of 2.97.
The background SUVmax was used as the segmenta-
tion threshold to provide the measured volume in each
experimental condition. Standardized Uptake Value (SUV)
max was worked out for each experimental condition on
the liver-like part of the phantom within a 20 to 30 cm3
ROI inside a healthy part of the liver. To have a more reli-
able value, 3 ROI were used when differences of less than
0.1 in the SUVmax values were obtained. Two additional
measurements were added when differences between 0.1
and 0.2 were obtained. No differences higher than 0.2
were obtained.
Patient selection
Patients with liver oligometastases eligible to SBRT treat-
ment were consecutively included in the study.
PET-CT and 4D PET-CT
All patients underwent a standard non-gated PET (150 sec-
onds acquisition per bed position) and a respiratory-gated
PET immediately afterwards. For a whole body non-gated
PET with a mean of 7 bed positions, the acquisition was
17.5 min. The respiratory-gated PET was done during one
bed position and took approximately 10 min.
The same CT scan was used for attenuation correction
and registration for both PET acquisitions. CT and PET
acquisition were made during uncoached quiet free
breathing. PET data were acquired 60 minutes post in-
jection of [18 F]FDG, using the list mode of a Siemens
CT fitted with four rings and time of flight. The activity
injected to the patients was 3.5 (±0.2) MBq/kg. The
transaxial field of view (FOV) was 50 cm and the length
of the axial direction was 21.6 cm, allowing covering the
whole liver in one step.
The respiratory gating system consisted in an abdom-
inal belt with a pressure sensor (AZ-733 V, Anzai Med-
ical Co, Tokyo, Japan). The pressure signal was recorded
and used for synchronized retrospective reconstructions.
Six PET phases distributed equally over the breathing
cycle were reconstructed for each respiratory-gated PET
scan data set.
CT images were acquired by using the following param-
eters: pitch: 1; rotation time: 0.8 s; reconstruction: slice
thickness of 2 mm and increment of 1 mm. The voltage
was 120 kV and the current-time reference was 120 mAs.
The liver metastases were assessed in dimension on
the different PET acquisitions with the diagnostic soft-
ware from Siemens (True D) by creating Regions Of
Figure 1 Anthropomorphic phantom Torso experiments: 3-dimensional CT and PET/CT views showing accurate volume determination
on PET compared to CT (reference values for diameters) using the healthy liver background SUVmax segmentation method.
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Standardized Uptake Value (SUV) threshold.
Target volume definition
Target volumes were delineated using the software Mim-





BTV phase 2 
Figure 2 Definition of target volumes and corresponding margins. BT
gated 150 second PET exam. CTV: clinical target volume, manually modified
Volume, obtained by adding a 5 mm radial and a 10 mm craniocaudal ma
(phase 1) of the 4D-PET. BTV phase 2: representation of the volume obtaine
Target Volume, volume obtained by merging the tumor volume on the six
by adding an isotropic 3 mm-margin to the BITV.All volume measurements were made with Mimvista.
The CT scan associated with the respiratory-gated PET
exam was used as the planning CT scan. All the volumes
are summarized on Figure 2.
For liver metastases segmentation and volume com-





V: Biological Target Volume, semi-automatically determined on non-
from the BTV to make it more accurate. PTV: manual Planning Target
rgin. BTV phase 1: representation of the volume obtained on one phase
d on one phase (phase 2) of the 4D PET. BITV: Biological Internal
phases of the 4D PET. PTVg: gated Planning Target Volume, obtained
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in tumor volume measurement.
Biological Target Volumes (BTV) were semi-automatically
generated on the gated PET.
Normal liver Standardized Uptake Value (SUV) max
was worked out for each patient within a 20 to 30 cm3
ROI inside a healthy part of the liver. To have a more
reliable value, 3 ROI were used when differences of less
than 0.1 in the SUVmax values were obtained. Two add-
itional measurements were added when differences be-
tween 0.1 and 0.2 were obtained. No differences higher
than 0.2 were obtained. These values were determined
on the respiratory-gated phase of the PET exam identical
to the respiratory phase of the CT scan of reference.
This phase was chosen to avoid spatial errors in the
determination of the ROI because of respiratory tumor
motion. The threshold used to obtain the gated BTV
was thus individualized for each patient as this normal
liver Standardized Uptake Value (SUV) max. We used
SUV normalized to body weight. This method was
chosen to give the best differential value between tumor
and normal liver (a SUV value above the SUV max of
the normal liver was thus considered as part of the
tumor). By applying the threshold to the six gated phases
of the respiratory-gated PET exam and by adding these
volumes, a Biological Internal Target Volume (BITV)
was generated for each lesion of every patient. An iso-
tropic 3 mm margin was added to account for set-up
margins (patient positioning). The resulting volume was
called gated Planning Target Volume (PTVg).
This 3 mm margin was chosen in accordance with the
study of Hawkins et al., which demonstrated, by a kV
cone-beam CT-based study, population random setup
errors of 2.7 mm, 2.3 mm, and 3.0 mm respectively in
the craniocaudal (CC), medio-lateral (ML) and antero-
posterior (AP) directions [17]. Another study by Dawson
et al. evaluated population random setup errors to be
2.5 mm (CC), 2.8 mm (ML), and 2.9 mm (AP) [18].
Smaller set-up errors less than 2 mm have been reported
by other authors, making an isotropic 3 mm margin
probably sufficient when a proper repositioning and on-
line IGRT system is provided [19].
Images from the non-gated PET acquisition were used
to help manual target volume definition. Furthermore, a
non-gated BTV was semi-automatically created from the
non-gated PET exam to help with manual target volume
delineation on planning CT fused with non-gated PET,
using the same method as for the respiratory-gated PET:
normal liver SUV max was worked out for each patient
within a 20 to 30 cm3 ROI inside a healthy part of the
liver. To have a more reliable value, 3 ROI were used
when differences of less than 0.1 in the SUVmax values
were obtained. Two additional measurements were added
when differences between 0.1 and 0.2 were obtained. Nodifferences higher than 0.2 were obtained. The threshold
used to obtain the non-gated BTV was thus individualized
for each patient as this normal liver body weighted-SUV
max. CT scan with contrast and/or MRI with contrast
were available for target volume definition. A radiation
oncologist experienced with liver SBRT treatment manu-
ally worked out the volumes, to make them more accur-
ate, taking into account the CT scan and MRI, to better
represent the real tumoral volume and excluding bones,
lung and other organs-at-risk (OAR) included in the BTV.
The resulting volume was called clinical target volume
(CTV). An additional margin was applied to account
for tumor motion and set-up margins to create a manual
Planning Target Volume (PTV). A 5 mm radial and a
10 mm craniocaudal margin were chosen in accordance
to the majority of the published studies on liver metasta-
ses SBRT, and considered the minimal margin to account
for target volume motion and set-up margins during liver
SBRT, even when active breathing control is used [6-8].
Statistical analysis
Target volumes evaluation was based on the volumes cal-
culated by the treatment planning system. PTV and PTVg
were compared for each lesion, as well as BTV with BITV.
Non-parametric Wilcoxon matched pair tests were used
for comparison between PTV and PTVg, and between
BTV and BITV. A two-tailed p value <0.05 was used to in-
dicate statistical significance. All analyses were made with
Instat (Graphpad Software, La Jolla, CA, USA).
Results
Segmentation assessment on phantoms
Differences between measured and real volumes varied
from −42% to 137% using the Jaszczak phantom. Differ-
ences between measured and real volumes were 34%
and 12% corresponding to mean measured volumes of
21.45 cm for the 16 cc sphere and 8.5 cm for the 8 cc
sphere respectively, using the Torso phantom. Figure 1
shows 3-dimensional CT and PET/CT views and volume
determination using the healthy liver background SUV-
max segmentation method.
Patient characteristics
A total of 8 patients were prospectively included in the
study between December 2011 and April 2012. The total
number of liver lesions evaluated was 14. Patient charac-
teristics are shown in Table 1. The maximal diameter of
the lesions was between 2 and 4.8 cm.
SUV
One interesting result is that SUV threshold was higher
with the respiratory-gated exams than with the non-
gated ones. Median SUV threshold in respiratory-gated
exams and non-gated exams were respectively 4.45 (min:
Table 1 Patient characteristics
Patient
number
Age Gender Primary cancer Liver
metastases
Maximal diameter





1 75 F Ampulloma 3 3.2 4.3 3.8
2 76 M Colon 4 4.8 4.6 4
3 78 M Lung 1 2 5 5
4 65 M Esophageal 2 5 4.9 3.7
5 61 F Lung 3 3.5 4.1 3
6 65 M Colon 2 2 4.3 3.4
7 64 F Ovarian 11 2.5 4.8 3.8
8 67 M Lung 2.7 3.9 3.7
Figure 3 Undiagnosed liver metastasis discovered thanks to
the 4D PET exam (Upper part of the figure). This second
metastasis was not visible on the non respiratory-gated PET exam
(lower part of the figure).
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tailed P value was 0.0156, considered significant.
Metastases diagnosis
One undiagnosed liver metastasis was discovered thanks
to the 4D PET-CT exam for patient 1 (Figure 3). This me-
tastasis was located in segment 7 of the liver and was not
visible on non-gated PET or on CT scan with contrast.
Target volumes definition
Table 2 shows PTV and PTVg, BTV and BITV compari-
sons for each lesion and every patient.
Semi-automatically generated BTV from the non-gated
PET exams were significantly lower than the BITV ob-
tained from the respiratory gated PET: mean volume in cc
(minimal and maximal values in brackets) 7.7 (0.7-34.2) Vs
10.1 (1.4-39) respectively for BTV and BITV (p = 0.0031).
The use of the respiratory-gated PET exams and the
resulting BITV allowed a statistically significant decrease
in the Planning Target Volumes (PTV) (p = 0.0052).
Mean PTVg was 22 (5.8-73.2) and mean PTV was 33
(9.6-113). PTVg were smaller than PTV in all cases but
one. This exception corresponded to a metastasis adja-
cent to the lungs (Figure 4a). A representative example
of the other cases is given on Figure 4b.
Discussion
SBRT for liver metastases is able to precisely target the
lesions while minimizing normal tissue toxicity. Dose
escalation is limited by the tolerance of the surrounding
healthy liver tissue. Initial local control rates are very
good at 1 year but are then limited to 57 to 92% at
2 years, depending on the studies [1].
PET/CT imaging with [18 F]FDG is a well-established
imaging technique with clinical implications in oncology
for staging, re-staging and monitoring response to
therapy, including after SBRT [20]. New software develop-
ments have highlighted its value for target volume defin-
ition and contouring purposes. However, its usefulness for
radiotherapy planning has not been widely assessed and





PTV (cc) PTVg (cc) PTV/PTVg (%) BITV (cc) BTV (cc) BITV/BTV (%) CTV (cc) Whole liver
volume (cc)
1 1 30.4 24.7 123 9.9 5 198 5.4 1671
2 9.6 6.3 152 1.7 0.7 243 0.8 1671
2 1 29.8 41.8 71 21.6 9.4 230 5.6 1485
2 34.6 26.4 131 12.6 7.9 159 7.9 1485
3 1 12 5.8 207 1.4 0.7 200 1.1 1530
4 1 113 73.2 154 39 34.2 114 42 1293
2 52.8 34.4 153 17.3 14.9 116 14.6 1293
5 1 49.1 24.8 198 11.6 13.5 86 13.5 1758
2 23.2 12.4 187 4.7 4.5 104 4.5 1758
3 25.1 14.1 178 5.4 5 108 5 1758
6 1 20 10 200 3.5 3.2 109 3.4 2230
2 16.4 8.5 193 2.7 1.8 150 2.2 2230
7 1 29.3 13.6 215 5.4 4.8 113 5.3 1502
8 1 16.3 12.1 134 4.4 2.4 183 2.4 1206
Mean (+ − SD) 33 (+/−26.2) 22 (+/−18.3) 150 10.1 (+/−10.3) 7.7 (+/−8.8) 131
P value PTV Vs PTVg 0.0052 BITV Vs BTV 0.0031
PTV, PTVg, BTV and BITV are compared using non-parametric Wilcoxon paired tests. SD: standard deviation.
Figure 4 Examples of target volume delineation. a: Different target volumes obtained for a liver metastasis next to the diaphragm. The manual
contouring leads to inaccurate evaluation of the PTV. CT scan in the upper part, non respiratory-gated PET in the middle, and co-registrated non
respiratory-gated PET-CT in the lower part. CTV appears in dark blue, PTV in light blue, BITV in red and PTVg in magenta. b: Representative target
volumes obtained for a liver metastasis (patient 6). The manual contouring leads to an increase in the PTV as compared to the PTVg. CT scan in the
upper part, non respiratory-gated PET in the middle, and co-registrated non respiratory-gated PET-CT in the lower part. CTV appears in dark blue, PTV
in light blue, BITV in red and PTVg in magenta.
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http://www.ro-journal.com/content/9/1/127suffers from image degradation due to target movements
and lack of SUV threshold standardization. As breath-
holding is difficult to implement during PET/CT imaging
due to the duration of the procedure, images are affected
by motion artifacts and loss of contrast because of radio-
activity smearing around the moving lesion, especially
when the tumor is adjacent to the lungs.
Especially, cardiac and respiratory motion affects im-
aging because of organ displacements of up to 2 cm dur-
ing normal breathing [21,22]. Liver targets are particularly
exposed to respiratory motion, making a 5 mm radial and
a 10 mm craniocaudal margins probably inaccurate.
Since liver SBRT is a very precise technique in a tissue
exposed to radiation toxicity, any process that aims at
making radiotherapy planning more precise is of particu-
lar interest. 4D PET-CT techniques are new tools to try
to compensate the motion-induced image quality deg-
radation. It has been evaluated for lung tumors [14], and
has proven its clinical utility for lung tumor radiotherapy
planning [15].
In this study, we checked whether 4D PET-CT was a
reliable and feasible procedure for liver radiotherapy
treatment planning in order to be routinely integrated to
the management of SBRT patients. The use of PET-
based segmentation and volumes is often complex and it
is not clear how to accurately select the threshold value
for segmentation [23]. Given the lack of standardized
methods for liver segmentation, we developed a threshold-
based method to segment metastases with respect to
background SUVmax measured on patient healthy liver.
The liver segmentation method was thus individualized in
a timely and personalized fashion.
In lung cancer, 4D PET has been shown to better
match tumor motion than non-gated PET images
[24,25]. Unlike for lung tumors, no standard method has
been described for automatic liver tumor segmentation
using PET-CT [26-28]. The volume of the BTV mostly
depends on the segmentation method used and most of
these methods result in unsatisfactory volumes [29]. In
head and neck tumors, it has been shown that PET-
based tumor delineation yields more accurate and repro-
ducible results with signal to background ratio than with
manual/visual delineation (sensitive to window level set-
tings and operator dependent), isocontouring based on a
Standardized Uptake Value (SUV) of 2.5, or fixed per-
centage of the maximal SUV value (40% or 50%) delinea-
tion [30]. The signal to background method has been
validated on histology for head and neck cancer and its
threshold is adapted to an individual patient [31]. Its
feasibility for liver malignancies was shown experimen-
tally, with this method reliably estimating hepatic tumor
diameter. The feasibility was also shown with physio-
logical FDG liver uptake as the background value and a
personalized threshold segmentation method based onnormal liver SUVmax for tumor measurements. Al-
though the SUVmax might not be the best value and
peak and mean SUV might suffer fewer fluctuations, the
SUVmax is widely-used in clinical practice for its con-
venience, as reported in the clinics and supported by our
study. Additional studies evaluating these values for seg-
mentation will hopefully improve our methodology and
compare these methods to supposedly more reliable ones.
4D PET may have a potential for increased sensitivity
compared to non-gated PET exam and contrast-enhanced
CT scan as suggested by the discovery of an additional
undiagnosed lesion on both modalities in one patient.
Limitations of non-gated PET/CT include respiratory
motion blur, poor spatial resolution and/or partial volume
effect. Of clinical relevance, this lesion would have
remained untreated without the use of 4D PET.
Moreover, respiratory-gated PET/CT was able to signifi-
cantly decrease PTV as compared to a standard planning
procedure using non-respiratory gated PET/CT. Further-
more, as BTV was significantly lower than BITV, auto-
matic contouring based on non respiratory-gated exams
may underestimate the real internal target volumes (that
is the target volume accounting for respiratory motion)
because of image blurring and inaccurate SUV values.
Improving SBRT treatment planning could therefore
lead to a better protection of critical organs and further
dose escalation, both possibly providing increased benefit-
risk ratios.
Our study has a number of limitations. First of all, a
potential drawback is that planning CT scan was made
during non-gated acquisition, which implied matching a
selected PET phase with the CT.
Furthermore, planning contrast-enhanced CT scan and
planning MRI were not used in our study for radiother-
apy planning [8,9]. However, we limited this bias by inte-
grating PET-based imaging and semi-automatic PET-
based BTV directly registered with the planning CT scan
of reference that didn’t require additional hazardous
image co-registration or fusion [32-34]. Further in-
vestigations will be necessary to assess the role of a
respiratory-gated PET in addition to contrast-enhanced
CT scan as the standard planning procedure.
Conclusions
In comparison to non-gated PET, 4D PET may better
account for the respiratory movements of liver targets
and more appropriately evaluate internal target volumes.
Further, reduction of irradiated liver volumes may allow
for safer and potentially more efficient SBRT treatment.
Finally, it might become a valuable tool to improve
SBRT planning for liver metastases.
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